Rich Kodama

Rich Kodama

Auto-generated profile, based on publicly available information

Rich Kodama

Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JYJudy Yan
Judy Yan
SSSamantha N Steiger
Samantha N Steiger
RKRich Kodama
Rich Kodama
JFJerome Fender
Jerome Fender
CTCarrie Tan
Carrie Tan
MKMini Kamboj
Mini Kamboj
Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19–related hospitalization(s) compared to those who did not. Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19–related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73–18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69–19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.

3 December 2024 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
SUShauna Usiak
Shauna Usiak
AAAnoshe Aslam
Anoshe Aslam
JYJudy Yan
Judy Yan
JMJerin Madhavappallil
Jerin Madhavappallil
MBMarissa Bokhari
Marissa Bokhari
MKMini Kamboj
Mini Kamboj
Background: SARS-CoV-2 asymptomatic surveillance testing (AST) is a common strategy to minimize the risk of nosocomial infection in patients and healthcare personnel. In contrast to admission screening, post-admission AST was less widely adopted.Objective: This study describes the diagnostic yield of post-admission serial SARS-COV-2 testing in hospitalized patients at a large cancer center with mostly double-occupancy rooms.Design: Retrospective cohort study design. Post-admission SARS-CoV-2 tests were examined over a 18 month study period. Positive results were reviewed to determine true hospital-onset infections using a combination criteria of screening all sample cycle threshold (Ct) values >30, results of non-concordant repeat testing, and clinical symptoms.Results: Post-admission serial testing of 15,048 hospitalized patients during an 18-month study period at a tertiary care cancer center detected hospital-onset infection in 1.6% (n = 245 patients). Among all hospital-onset positive SARS-CoV-2 RNA tests, 13% were clinically false positive. Most true infections were mild to moderate in severity.Conclusions: In summary, post-admission serial testing in a high-risk setting is a low-yield strategy with several unfavorable effects and should no longer be routinely applied.

21 September 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
JLJustin Laracy
Justin Laracy
AGAthanasios Gatsis
Athanasios Gatsis
JYJudy Yan
Judy Yan
RKRich Kodama
Rich Kodama
MKMini Kamboj
Mini Kamboj
We evaluated the utility of nearly twelve thousand Streptococcus pneumoniae urine antigen tests at a tertiary cancer center. Overall, test positivity rate was low. Testing during hospital days 0–2 yielded a greater positivity rate than testing at hospital 3 or beyond (1.2% vs 0.89%, P = .15). This trend was preserved among patients with neutropenia (1.2% vs 0.68%; P = .30) and those who had received cellular therapy within the preceding year (1.3% vs 0.34%; P = .11).

7 April 2026 in Cytotherapy
Verified
Journal Article
Closed access
SASwarn Arya
Swarn Arya
RKRich Kodama
Rich Kodama
YLYuxuan Li
Yuxuan Li
GHGyuri Han
Gyuri Han
JSJalal Siddiqui
Jalal Siddiqui
GPGenovefa A. Papanicolaou
Genovefa A. Papanicolaou

7 July 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
JLJustin Laracy
Justin Laracy
JYJudy Yan
Judy Yan
RKRich Kodama
Rich Kodama
SUShauna Usiak
Shauna Usiak
EWEmily Walits
Emily Walits
MKMini Kamboj
Mini Kamboj
Background: Multiplex gastrointestinal polymerase chain reaction (GI-PCR) tests of the stool for the evaluation of infectious diarrhea are prone to false-positive target detections. However, there is no recommended testing approach in immunocompromised cancer patients who are often excluded from diagnostic stewardship protocols. The aim of this study was to evaluate the performance characteristics of the BioFire® FilmArray® GI-PCR and assess whether the findings support a diagnostic stewardship approach to limit testing among hospitalized cancer patients. Methods: A retrospective study of 29,727 GI-PCR tests was performed at Memorial Sloan Kettering Cancer Center in New York City, evaluating data from February 1, 2020, to January 29, 2025. All tests sent from all locations and across all patient types were included in the study. Results: The overall GI-PCR positivity rate was greatest in the outpatient setting at 23.4% and dropped at 15.6% in the early stage of admission (hospital days 0–2) and 10.1% in the late stage of admission (hospital day 3 and beyond). Across all subgroups analyzed, norovirus and Enteropathogenic E. coli (EPEC) were the most frequently detected targets with all remaining targets detected at rates below 2%. The low pathogen detection rate was preserved among patients with neutropenia and recipients of recent cellular therapy. Conclusion: BioFire FilmArray GI panel has low utility in the inpatient setting including for severely immunosuppressed hosts. These observations identify a potential opportunity for diagnostic stewardship and suggest that commonly applied testing restrictions may warrant further evaluation in immunocompromised oncology populations.